Disease Control Priorities, Third Edition (Volume 6)
Disease Control Priorities, Third Edition (Volume 6)

Author: King K. Holmes

Publisher: World Bank Publications

Published: 2017-11-06

Total Pages: 1027

ISBN-13: 1464805253

DOWNLOAD EBOOK

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Nanotechnology Based Approaches for Tuberculosis Treatment
Nanotechnology Based Approaches for Tuberculosis Treatment

Author: Prashant Kesharwani

Publisher: Academic Press

Published: 2020-06-10

Total Pages: 286

ISBN-13: 0128226110

DOWNLOAD EBOOK

Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis. - Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics - Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities - Covers the field thoroughly, from the pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis, to treatment approaches using nanotechnology and different nanocarriers

Host-Directed Therapies for Tuberculosis
Host-Directed Therapies for Tuberculosis

Author: Vishwanath Venketaraman

Publisher:

Published: 2020

Total Pages: 120

ISBN-13: 9783039435029

DOWNLOAD EBOOK

TB is considered as one of the oldest documented infectious diseases in the world and is believed to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the entire world's population has latent TB. Consequently, there has been a worldwide effort to eradicate and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb. Furthermore, when administered, many of the anti-TB drugs commonly present severe complications and side effects. Novel approaches to enhance the host immune responses to completely eradicate Mtb infection are urgently needed. This Special Issue will therefore cover most recent advances in the area of host-directed therapies for TB.

Advances in Host-Directed Therapies Against Tuberculosis
Advances in Host-Directed Therapies Against Tuberculosis

Author: Petros C. Karakousis

Publisher: Springer Nature

Published: 2020-12-03

Total Pages: 325

ISBN-13: 3030569055

DOWNLOAD EBOOK

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

Tuberculosis in Adults and Children
Tuberculosis in Adults and Children

Author: Dorothee Heemskerk

Publisher: Springer

Published: 2015-07-17

Total Pages: 71

ISBN-13: 3319191322

DOWNLOAD EBOOK

This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases.

Understanding the Host Immune Response Against Mycobacterium tuberculosis Infection
Understanding the Host Immune Response Against Mycobacterium tuberculosis Infection

Author: Vishwanath Venketaraman

Publisher: Springer

Published: 2018-09-26

Total Pages: 149

ISBN-13: 3319973673

DOWNLOAD EBOOK

According to the World Health Organization, approximately one third of the world’s population is latently infected with Mycobacterium tuberculosis (M. tb [LTBI]), of whom about 9 million have active tuberculosis (TB). It is estimated that approximately 2 million individuals die each year from active TB. An estimated 14.4% of these individuals have HIV and M. tb co-infection. TB has long been known to be one of the leading causes of death in HIV-infected individuals. Recent evidence now indicates that individuals with type 2 diabetes, the elderly, and chronic smokers are also increasingly susceptible to TB infection, the ability of their immune system to fight off active TB infection having been compromised by their condition. This book therefore aims to provide a detailed review of recent advances in the research that involves characterizing the host’s immune responses against TB infection in conditions such as HIV, diabetes, chronic cigarette smoking and aging, and strategies to restore favorable immune responses against this deadly pathogen.

Ending Neglect
Ending Neglect

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2000-08-31

Total Pages: 288

ISBN-13: 0309171946

DOWNLOAD EBOOK

Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the worldâ€"ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB.

Tuberculosis Drug Discovery and Development 2019
Tuberculosis Drug Discovery and Development 2019

Author: Giovanna Riccardi

Publisher: MDPI

Published: 2020-11-24

Total Pages: 296

ISBN-13: 3039432362

DOWNLOAD EBOOK

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.

Toman's Tuberculosis
Toman's Tuberculosis

Author: K. Toman

Publisher: World Health Organization

Published: 2004-06-23

Total Pages: 350

ISBN-13: 9241546034

DOWNLOAD EBOOK

This is the second edition of a reference work aimed at all those concerned with dealing with tuberculosis control in developing countries. The book follows in the tradition of Kurt Toman's original work in this field, with the text set out in a question and answer format, grouped under three headings: case detection; treatment, and monitoring. The threat of tuberculosis is still potent, with two million deaths globally. This new edition, containing contributions from a number of experts in this field, addresses the resurgence of tuberculosis, and the emergence of multidrug-resistant bacilli, and the growth of HIV-infected individuals with tuberculosis, as well as recent scientific developments.